Patient characteristics
| Characteristics | Entire cohort (n=88) | Survey respondents (n=63) |
| Female, n (%) | 52 (59) | 37 (59) |
| Age, mean (SD) years | 64.3 (11.8) | 63.4 (11.5) |
| Caucasian, n (%) | 75 (85) | 56 (89) |
| BMI, mean (SD) | 28.3 (8.4) | 28.4 (8.8) |
| Hypertension, n (%) | 34 (39) | 23 (37) |
| Diabetes, n (%) | 9 (10) | 7 (11) |
| Pulmonary disorder, n (%) | 8 (9) | 4 (6.3) |
| Cancer type, n (%) | ||
| Melanoma | 24 (27) | 17 (27) |
| Renal | 19 (22) | 14 (22) |
| Urothelial | 10 (11) | 10 (16) |
| NSCLC | 15 (17) | 8 (13) |
| Other | 17 (19) | 14 (22) |
| Active ICI treatment* | ||
| Yes | 45 (51) | 25 (40) |
| No | 40 (45) | 38 (60) |
| Unknown | 3 (3) | 0 (0) |
| Months since last follow-up, med (IQR) | 5 (2,9) | 3 (1,8) |
| ICI regimen, n (%) | ||
| Monotherapy PD-1/PD-L1 | 62 (70) | 44 (70) |
| Combination | 26 (30) | 19 (30) |
| Cancer response, n (%) | ||
| CR/PR/stable | 67 (82) | 49 (78) |
| Progression | 15 (18) | 10 (22) |
| Rheumatologic irAE, n (%) | ||
| Small joint arthritis | 32 (36) | 22 (35) |
| Activated OA | 15 (17) | 9 (14) |
| PMR | 8 (9) | 7 (11) |
| Large joint arthritis | 8 (9) | 6 (10) |
| Arthralgia | 9 (10) | 6 (10) |
| Sicca syndrome | 3 (3) | 3 (5) |
| Myositis | 2 (2) | 2 (3) |
| Other† | 11 (13) | 8 (13) |
| Arthritis medications‡, n (%) | ||
| No medications | 25 (28) | 19 (30) |
| NSAIDs | 13 (15) | 9 (14) |
| Steroids | 39 (44) | 26 (41) |
| HCQ | 11 (15) | 6 (10) |
| MTX | 5 (6) | 4 (6) |
| Anti-TNF | 5 (6) | 5 (6) |
| Tocilizumab | 3 (3) | 3 (5) |
| Arthritis medications changed due to the pandemic | -- | 0 (0) |
*Active ICI treatment=received a dose of ICI within the 6 months preceding the survey.
†Other diagnoses include eosinophilic fasciitis, gout, enthesitis, costochondritis, bursitis.
‡Totals do not add up to 100% given that patients can be on multiple medications at a given time.
BMI, body mass index; CR, complete response; HCQ, hydroxychloroquine; ICI, immune checkpoint inhibitor; irAE, immune-related adverse effect; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; OA, osteoarthritis; PMR, polymyalgia rheumatica; PR, partial response; TNF, tumor necrosis factor.